Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Akeso, Inc.
  6. News
  7. Summary
    9926   KYG0146B1032

AKESO, INC.

(9926)
  Report
Delayed Hong Kong Stock Exchange  -  02:05:26 2023-02-06 am EST
45.20 HKD   -7.57%
01/26Akeso Received First Tranche of US$300 Million Upfront Payment from Summit! Summit Is Accelerating Clinical Development of Ivonescimab
PR
01/26Akeso Receives First Tranche of Payment for Ivonescimab License Deal with Summit Therapeutics; Shares Climb 6%
MT
01/23Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Akeso Eyes Issuance of Ordinary Shares on Science and Technology Innovation Board of Shanghai Bourse

12/06/2022 | 12:17am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AKESO, INC. -7.57% 45.2 Delayed Quote.13.72%
SHANGHAI A INDEX -0.68% 3394.72 Real-time Quote.5.63%
SHANGHAI STOCK EXCHANGE B SHARES INDEX -0.52% 296.4239 Real-time Quote.5.59%
All news about AKESO, INC.
01/26Akeso Received First Tranche of US$300 Million Upfront Payment from Summit! Summit Is A..
PR
01/26Akeso Receives First Tranche of Payment for Ivonescimab License Deal with Summit Therap..
MT
01/23Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative B..
AQ
01/20Summit Therapeutics Closes Deal With Akeso to Commercialize Lung Cancer Therapy
MT
01/15Akeso, Inc. Announces China NMPA Approved Anniko for First-Line Treatment of Locally Ad..
CI
01/15Chinese Regulator Grants Marketing Approval to Akeso, Sino Biopharmaceutical's Lung Can..
MT
2022Akeso Inc. Announces JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) ..
CI
2022Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License..
AQ
2022Sector Update: Health Care Stocks Flat To Lower Premarket Wednesday
MT
2022Nomura Adjusts Akeso's Price Target to HK$46.04 From HK$31.54, Keeps at Buy
MT
More news
Analyst Recommendations on AKESO, INC.
More recommendations
Financials
Sales 2022 851 M 126 M 126 M
Net income 2022 -1 119 M -165 M -165 M
Net cash 2022 709 M 105 M 105 M
P/E ratio 2022 -31,0x
Yield 2022 -
Capitalization 35 449 M 5 242 M 5 242 M
EV / Sales 2022 40,8x
EV / Sales 2023 8,10x
Nbr of Employees 2 289
Free-Float 61,6%
Chart AKESO, INC.
Duration : Period :
Akeso, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKESO, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 42,15 CNY
Average target price 45,52 CNY
Spread / Average Target 8,00%
EPS Revisions
Managers and Directors
Yu Xia Chairman, President & Chief Executive Officer
Xiao Jie Xi Chief Financial Officer & Co-Secretary
Baiyong Li Executive Director, Chief Scientific Officer & SVP
Jun Wen Zeng Independent Non-Executive Director
Yan Xu Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
AKESO, INC.13.72%5 242
REGENERON PHARMACEUTICALS, INC.8.54%83 640
VERTEX PHARMACEUTICALS4.24%77 269
WUXI APPTEC CO., LTD.15.80%40 679
BIONTECH SE-5.43%34 523
BEIGENE, LTD.16.80%26 752